GlassScriptPhysician profile
William K White
NPI 1568516730
$1,394.42
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $28.87 · 2021: $497 · 2022: $188 · 2023: $230 · 2024: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $230.79 | 2021 | |
| Abbvie INC. | $136.85 | 2021-2023 | Vraylar |
| Novartis Pharmaceuticals Corporation | $117.93 | 2023-2024 | |
| Amgen INC. | $105.94 | 2019-2024 | Tepezza, Otezla, Repatha |
| Sumitomo Pharma America, INC. | $96.06 | 2023-2024 | Gemtesa |
| Ascensia Diabetes Care US INC. | $83.40 | 2019 | |
| Astellas Pharma US INC | $75.53 | 2019-2021 | |
| Mylan Specialty L.P. | $74.99 | 2021-2023 | Yupelri |
| Paratek Pharmaceuticals, INC. | $67.22 | 2022-2024 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $56.28 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.88 | 2021-2022 | |
| Medtronic, INC. | $32.37 | 2024 | Minimed 780g |
| Vifor Pharma, INC. | $28.64 | 2024 | Zemaira |
| Janssen Pharmaceuticals, INC | $25.11 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.96 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $21.63 | 2024 | Rybelsus |
| Nestle Healthcare Nutrition INC. | $19.75 | 2022 | |
| Dexcom, INC. | $19.43 | 2023 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $18.90 | 2022 | |
| Abbott Laboratories | $17.94 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.45 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.10 | 2022 | |
| Adlon Therapeutics L.P. | $16.91 | 2021 | |
| Pfizer INC. | $15.67 | 2021 | |
| Esperion Therapeutics, INC. | $12.58 | 2021 | |
| Allergan, INC. | $11.98 | 2020 | |
| Eisai INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.